ArticleChemMedChem2019
Six Laws of Open Source Drug Discovery.
Article in ChemMedChem, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.Chemical Society reviews · 2026Review
- Investigations of amination reactions on an antimalarial 1,2,4-triazolo[4,3-Beilstein journal of organic chemistry · 2025Article
- Open Source Code Contributions to Global Health: The Case of Antimalarial Drug Discovery.ACS medicinal chemistry letters · 2024Article
- Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase.Nature communications · 2024Article
- Open Source Antibiotics: Simple Diarylimidazoles Are Potent against Methicillin-ResistantACS infectious diseases · 2023Article
- Actions of Camptothecin Derivatives on Larvae and Adults of the Arboviral VectorMolecules (Basel, Switzerland) · 2021Article
- A critical overview of computational approaches employed for COVID-19 drug discovery.Chemical Society reviews · 2021Review
- Structural Requirements for Dihydrobenzoxazepinone Anthelmintics: Actions against Medically Important and Model Parasites:ACS infectious diseases · 2021Article
- There is no market for new antibiotics: this allows an open approach to research and development.Wellcome open research · 2021Article
- Anthelmintic drug discovery: target identification, screening methods and the role of open science.Beilstein journal of organic chemistry · 2020Review
- Six Laws of Open Source Drug Discovery.ChemMedChem · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Six to swear by! Society needs effective and affordable medicines. We currently have at our disposal essentially one system to discover and develop drugs, and there are many areas where this system struggles to deliver, for example to combat antimicrobial resistance, or tropical diseases, or dementia. It is sensible to cultivate alternative, competing approaches to drug discovery and development. A genuinely new alternative is to open up the entire research cycle, abandoning secrecy altogether. This "open source" approach has now been trialed and the lessons learned distilled to six laws of operation that help to clarify working practices. This article examines and explains those laws, which can be adopted by anyone wishing to create medicines using an inclusive, public process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.